1
|
Bonnard D, Le Rouzic E, Singer MR, Yu Z, Le Strat F, Batisse C, Batisse J, Amadori C, Chasset S, Pye VE, Emiliani S, Ledoussal B, Ruff M, Moreau F, Cherepanov P, Benarous R. Biological and Structural Analyses of New Potent Allosteric Inhibitors of HIV-1 Integrase. Antimicrob Agents Chemother 2023; 67:e0046223. [PMID: 37310224 PMCID: PMC10353390 DOI: 10.1128/aac.00462-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Accepted: 05/08/2023] [Indexed: 06/14/2023] Open
Abstract
HIV-1 integrase-LEDGF allosteric inhibitors (INLAIs) share the binding site on the viral protein with the host factor LEDGF/p75. These small molecules act as molecular glues promoting hyper-multimerization of HIV-1 IN protein to severely perturb maturation of viral particles. Herein, we describe a new series of INLAIs based on a benzene scaffold that display antiviral activity in the single digit nanomolar range. Akin to other compounds of this class, the INLAIs predominantly inhibit the late stages of HIV-1 replication. A series of high-resolution crystal structures revealed how these small molecules engage the catalytic core and the C-terminal domains of HIV-1 IN. No antagonism was observed between our lead INLAI compound BDM-2 and a panel of 16 clinical antiretrovirals. Moreover, we show that compounds retained high antiviral activity against HIV-1 variants resistant to IN strand transfer inhibitors and other classes of antiretroviral drugs. The virologic profile of BDM-2 and the recently completed single ascending dose phase I trial (ClinicalTrials.gov identifier: NCT03634085) warrant further clinical investigation for use in combination with other antiretroviral drugs. Moreover, our results suggest routes for further improvement of this emerging drug class.
Collapse
Affiliation(s)
| | | | - Matthew R. Singer
- Chromatin Structure and Mobile DNA Laboratory, Francis Crick Institute, London, United Kingdom
| | - Zhe Yu
- Chromatin Structure and Mobile DNA Laboratory, Francis Crick Institute, London, United Kingdom
| | | | - Claire Batisse
- IGBMC, INSERM, CNRS, Université de Strasbourg, Illkirch, France
| | - Julien Batisse
- IGBMC, INSERM, CNRS, Université de Strasbourg, Illkirch, France
| | - Céline Amadori
- Biodim, Romainville, France
- Université Paris Cité, Institut Cochin, INSERM, CNRS, Paris, France
| | | | - Valerie E. Pye
- Chromatin Structure and Mobile DNA Laboratory, Francis Crick Institute, London, United Kingdom
| | | | | | - Marc Ruff
- IGBMC, INSERM, CNRS, Université de Strasbourg, Illkirch, France
| | | | - Peter Cherepanov
- Chromatin Structure and Mobile DNA Laboratory, Francis Crick Institute, London, United Kingdom
- Department of Infectious Disease, St. Mary's Campus, Imperial College London, London, United Kingdom
| | | |
Collapse
|
2
|
Bobko MA, Elward JM, Naidu BN, Nieves-Quinones YE, Reiher CA, Su Q, Sun L, Woodard J, Xie S, Yang W, Yin Y. Expeditious Synthesis of a Potent Allosteric HIV-1 Integrase Inhibitor GSK3839919A. Org Process Res Dev 2023. [DOI: 10.1021/acs.oprd.2c00343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Affiliation(s)
- Mark A. Bobko
- Drug Substance Development, GSK, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Jennifer M. Elward
- Molecular Design, GSK, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | | | - Yexenia E. Nieves-Quinones
- Drug Substance Development, GSK, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Christopher A. Reiher
- Drug Substance Development, GSK, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Qiaogong Su
- Drug Substance Development, GSK, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Liang Sun
- Chemistry Service Unit, WuXi AppTec Co., Ltd., 168 Nanhai Road, Tianjin 300457, People’s Republic of China
| | - John Woodard
- Drug Substance Development, GSK, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Shiping Xie
- Drug Substance Development, GSK, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Wuxing Yang
- Chemistry Service Unit, WuXi AppTec Co., Ltd., 168 Nanhai Road, Tianjin 300457, People’s Republic of China
| | - Yunxing Yin
- Chemistry Service Unit, WuXi AppTec Co., Ltd., 168 Nanhai Road, Tianjin 300457, People’s Republic of China
| |
Collapse
|
3
|
Sharma S, Utreja D. Synthesis and antiviral activity of diverse heterocyclic scaffolds. Chem Biol Drug Des 2022; 100:870-920. [PMID: 34551197 DOI: 10.1111/cbdd.13953] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2021] [Revised: 09/07/2021] [Accepted: 09/11/2021] [Indexed: 01/25/2023]
Abstract
Heterocyclic moieties form a major part of organic chemistry as they are widely distributed in nature and have wide scale practical applications ranging from extensive clinical use to diverse fields such as medicine, agriculture, photochemistry, biocidal formulations, and polymer science. By virtue of their therapeutic properties, they could be employed in combating many infectious diseases. Among the common infectious diseases, viral infections are of great public health importance worldwide. Thus, there is an urgent need for the discovery and development of antiviral drugs and clinical methods to prevent various viral infections so as to increase the life expectancy. This review presents the comprehensive overview of the synthesis and antiviral activity of different heterocyclic compounds 2015 onwards, which aids in present knowledge and helps the researchers and other stakeholders to explore their field.
Collapse
Affiliation(s)
- Shivali Sharma
- Department of Chemistry, College of Basic Sciences and Humanities, Punjab Agricultural University, Ludhiana, India
| | - Divya Utreja
- Department of Chemistry, College of Basic Sciences and Humanities, Punjab Agricultural University, Ludhiana, India
| |
Collapse
|
4
|
Parcella K, Patel M, Tu Y, Eastman K, Peese K, Gillis E, Belema M, Dicker IB, McAuliffe B, Ding B, Falk P, Simmermacher J, Parker DD, Sivaprakasam P, Khan JA, Kish K, Lewis H, Hanumegowda U, Jenkins S, Kadow JF, Krystal M, Meanwell NA, Naidu BN. Scaffold modifications to the 4-(4,4-dimethylpiperidinyl) 2,6-dimethylpyridinyl class of HIV-1 allosteric integrase inhibitors. Bioorg Med Chem 2022; 67:116833. [PMID: 35605346 DOI: 10.1016/j.bmc.2022.116833] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2022] [Revised: 05/12/2022] [Accepted: 05/13/2022] [Indexed: 11/17/2022]
Abstract
Allosteric integrase inhibitors (ALLINIs) of HIV-1 may hold promise as a novel mechanism for HIV therapeutics and cure. Scaffold modifications to the 4-(4,4-dimethylpiperidinyl) 2,6-dimethylpyridinyl class of ALLINIs provided a series of potent compounds with differentiated 5/6 fused ring systems. Notably, inhibitors containing the 1,2,4-triazolopyridine and imidazopyridine core exhibited single digit nM antiviral potency and low to moderate clearance after intravenous (IV) dosing in rat pharmacokinetic (PK) studies. The 1,2,4-triazolopyridines showed a higher oral exposure when compared to the imidazopyridines. Further modifications to the C5 substituent of the 1,2,4-triazolopyridines resulted in a new lead compound, which had improved rat IV/PO PK compared to the former lead compound GSK3739936, while maintaining antiviral potency. Structure-activity relationships (SAR) and rat pharmacokinetic profiles of this series are discussed.
Collapse
Affiliation(s)
- Kyle Parcella
- ViiV Healthcare, 36 East Industrial Road, Branford, CT 06405, USA.
| | - Manoj Patel
- ViiV Healthcare, 36 East Industrial Road, Branford, CT 06405, USA
| | - Yong Tu
- Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, NJ 08543-4000, USA(1)
| | - Kyle Eastman
- Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, NJ 08543-4000, USA(1)
| | - Kevin Peese
- ViiV Healthcare, 36 East Industrial Road, Branford, CT 06405, USA
| | - Eric Gillis
- ViiV Healthcare, 36 East Industrial Road, Branford, CT 06405, USA
| | - Makonen Belema
- Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, NJ 08543-4000, USA(1)
| | - Ira B Dicker
- ViiV Healthcare, 36 East Industrial Road, Branford, CT 06405, USA
| | - Brian McAuliffe
- ViiV Healthcare, 36 East Industrial Road, Branford, CT 06405, USA
| | - Bo Ding
- ViiV Healthcare, 36 East Industrial Road, Branford, CT 06405, USA
| | - Paul Falk
- ViiV Healthcare, 36 East Industrial Road, Branford, CT 06405, USA
| | | | - Dawn D Parker
- ViiV Healthcare, 36 East Industrial Road, Branford, CT 06405, USA
| | - Prasanna Sivaprakasam
- Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, NJ 08543-4000, USA(1)
| | - Javed A Khan
- Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, NJ 08543-4000, USA(1)
| | - Kevin Kish
- Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, NJ 08543-4000, USA(1)
| | - Hal Lewis
- Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, NJ 08543-4000, USA(1)
| | | | - Susan Jenkins
- ViiV Healthcare, 36 East Industrial Road, Branford, CT 06405, USA
| | - John F Kadow
- ViiV Healthcare, 36 East Industrial Road, Branford, CT 06405, USA
| | - Mark Krystal
- ViiV Healthcare, 36 East Industrial Road, Branford, CT 06405, USA
| | - Nicholas A Meanwell
- Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, NJ 08543-4000, USA(1)
| | | |
Collapse
|
5
|
Parcella K, Wang T, Eastman K, Zhang Z, Yin Z, Patel M, Tu Y, Zheng BZ, Walker MA, Saulnier MG, Frennesson D, Bowsher M, Gillis E, Peese K, Belema M, Cianci C, Dicker IB, McAuliffe B, Ding B, Falk P, Simmermacher J, Parker DD, Sivaprakasam P, Kish K, Lewis H, Hanumegowda U, Jenkins S, Kadow JF, Krystal M, Meanwell NA, Naidu BN. Discovery and Preclinical Profiling of GSK3839919, a Potent HIV-1 Allosteric Integrase Inhibitor. ACS Med Chem Lett 2022; 13:972-980. [DOI: 10.1021/acsmedchemlett.2c00115] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2022] [Accepted: 05/04/2022] [Indexed: 11/28/2022] Open
Affiliation(s)
- Kyle Parcella
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - Tao Wang
- Research and Early Development, Bristol Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Kyle Eastman
- Research and Early Development, Bristol Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Zhongxing Zhang
- Research and Early Development, Bristol Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Zhiwei Yin
- Research and Early Development, Bristol Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Manoj Patel
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - Yong Tu
- Research and Early Development, Bristol Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Barbara Zhizhen Zheng
- Research and Early Development, Bristol Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Michael A. Walker
- Research and Early Development, Bristol Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Mark G. Saulnier
- Research and Early Development, Bristol Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - David Frennesson
- Research and Early Development, Bristol Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Michael Bowsher
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - Eric Gillis
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - Kevin Peese
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - Makonen Belema
- Research and Early Development, Bristol Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Christopher Cianci
- Research and Early Development, Bristol Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Ira B. Dicker
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - Brian McAuliffe
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - Bo Ding
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - Paul Falk
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - Jean Simmermacher
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - Dawn D. Parker
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - Prasanna Sivaprakasam
- Research and Early Development, Bristol Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Kevin Kish
- Research and Early Development, Bristol Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Hal Lewis
- Research and Early Development, Bristol Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Umesh Hanumegowda
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - Susan Jenkins
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - John F. Kadow
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - Mark Krystal
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - Nicholas A. Meanwell
- Research and Early Development, Bristol Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - B. Narasimhulu Naidu
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| |
Collapse
|
6
|
Li C, Zhang F, Li T, Liu Z, Shen Z. A facile three‐component catalyst‐free strategy: Synthesis of indeno[1,2‐b][1,6]naphthyridine‐1,10(2H)‐dione derivatives in water. ASIAN J ORG CHEM 2022. [DOI: 10.1002/ajoc.202200145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Chunmei Li
- Shaoxing University School of Chemistry and Chemical Engineering CHINA
| | - Furen Zhang
- Zhejiang Key Laboratory of Alternative Technologies for Fine Chemicals Process School of Chemistry and Chemical Engineering 508 West Huancheng Road 312000 Shaoxing CHINA
| | - Tianci Li
- Zhejiang University of Technology Zhaohui Campus: Zhejiang University of Technology College of Chemical Engineering CHINA
| | - Zhiyuan Liu
- Zhejiang University of Technology Zhaohui Campus: Zhejiang University of Technology College of Chemical Engineering CHINA
| | - Zhenlu Shen
- Zhejiang University of Technology Zhaohui Campus: Zhejiang University of Technology College of Chemical Engineering CHINA
| |
Collapse
|
7
|
Dolna M, Nowacki M, Danylyuk O, Brotons-Rufes A, Poater A, Michalak M. NHC-BIAN-Cu(I)-Catalyzed Friedländer-Type Annulation of 2-Amino-3-(per)fluoroacetylpyridines with Alkynes on Water. J Org Chem 2022; 87:6115-6136. [PMID: 35394784 PMCID: PMC9087358 DOI: 10.1021/acs.joc.2c00380] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Abstract
![]()
The direct catalytic
alkynylation/dehydrative cyclization of 2-amino-3-trifluoroacetyl-pyridines
on water was developed for the efficient synthesis of a broad range
of fluorinated 1,8-naphthyridines from terminal alkynes. A novel N-heterocyclic
carbene (NHC) ligand system that combines a π-extended acenaphthylene
backbone with sterically bulky pentiptycene pendant groups was successfully
utilized in a copper- or silver-mediated cyclization. Computational
analysis of the reaction pathway supports our explanation of the different
experimental conversions and yields for the set of copper and silver
catalysts. The impact of steric hindrance at the metal center and
the flexibility of substituents on the imidazole ring of the NHC on
catalytic performance are also discussed.
Collapse
Affiliation(s)
- Magdalena Dolna
- Institute of Organic Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland
| | - Michał Nowacki
- Institute of Organic Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland
| | - Oksana Danylyuk
- Institute of Physical Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland
| | - Artur Brotons-Rufes
- Institut de Química Computacional i Catàlisi and Departament de Química, Universitat de Girona, c/ M. Aurèlia Capmany 69, 17003 Girona, Catalonia, Spain
| | - Albert Poater
- Institut de Química Computacional i Catàlisi and Departament de Química, Universitat de Girona, c/ M. Aurèlia Capmany 69, 17003 Girona, Catalonia, Spain
| | - Michał Michalak
- Institute of Organic Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland
| |
Collapse
|
8
|
Chauthe SK, Sidduri P, Reddy M, Sistla R, Byri V, Uttaravalli MD, Botlagunta M, Kumar H, Gupta A, Gupta AK, Bajpai L, Bagadi M, Mathur A. RP-HPLC separation of interconvertible rotamers of a 5-tetrahydroisoquinolin-6-yl-pyridin-3-yl acetic acid derivative and confirmation by VT NMR and DFT study. J Pharm Biomed Anal 2022; 212:114675. [DOI: 10.1016/j.jpba.2022.114675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2021] [Revised: 02/14/2022] [Accepted: 02/14/2022] [Indexed: 10/19/2022]
|
9
|
Naidu BN, Patel M, McAuliffe B, Ding B, Cianci C, Simmermacher J, Jenkins S, Parker DD, Sivaprakasam P, Khan JA, Kish K, Lewis H, Hanumegowda U, Krystal M, Meanwell NA, Kadow JF. Design, Synthesis, and Preclinical Profiling of GSK3739936 (BMS-986180), an Allosteric Inhibitor of HIV-1 Integrase with Broad-Spectrum Activity toward 124/125 Polymorphs. J Med Chem 2022; 65:4949-4971. [PMID: 35235334 DOI: 10.1021/acs.jmedchem.1c02169] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Allosteric HIV-1 integrase inhibitors (ALLINIs) have garnered special interest because of their novel mechanism of action: they inhibit HIV-1 replication by promoting aberrant integrase multimerization, leading to the production of replication-deficient viral particles. The binding site of ALLINIs is in a well-defined pocket formed at the interface of two integrase monomers that is characterized by conserved residues along with two polymorphic amino acids at residues 124 and 125. The design, synthesis, and optimization of pyridine-based allosteric integrase inhibitors are reported here. Optimization was conducted with a specific emphasis on the inhibition of the 124/125 polymorphs such that the designed compounds showed excellent potency in vitro against majority of the 124/125 variants. In vivo profiling of promising preclinical lead 29 showed that it exhibited a good pharmacokinetic (PK) profile in preclinical species, which resulted in a low predicted human efficacious dose. However, findings in rat toxicology studies precluded further development of 29.
Collapse
Affiliation(s)
- B Narasimhulu Naidu
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - Manoj Patel
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - Brian McAuliffe
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - Bo Ding
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - Christopher Cianci
- Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, New Jersey 08543, United States
| | - Jean Simmermacher
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - Susan Jenkins
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - Dawn D Parker
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - Prasanna Sivaprakasam
- Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, New Jersey 08543, United States
| | - Javed A Khan
- Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, New Jersey 08543, United States
| | - Kevin Kish
- Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, New Jersey 08543, United States
| | - Hal Lewis
- Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, New Jersey 08543, United States
| | - Umesh Hanumegowda
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - Mark Krystal
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| | - Nicholas A Meanwell
- Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, New Jersey 08543, United States
| | - John F Kadow
- ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405, United States
| |
Collapse
|
10
|
Adu-Ampratwum D, Pan Y, Koneru PC, Antwi J, Hoyte AC, Kessl J, Griffin PR, Kvaratskhelia M, Fuchs JR, Larue RC. Identification and Optimization of a Novel HIV-1 Integrase Inhibitor. ACS OMEGA 2022; 7:4482-4491. [PMID: 35155940 PMCID: PMC8829933 DOI: 10.1021/acsomega.1c06378] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/12/2021] [Accepted: 01/13/2022] [Indexed: 05/17/2023]
Abstract
Human immunodeficiency virus-1 (HIV-1) is the causative agent of acquired immunodeficiency syndrome (AIDS). HIV-1, like all retroviruses, stably integrates its vDNA copy into host chromatin, a process allowing for permanent infection. This essential step for HIV-1 replication is catalyzed by viral integrase (IN) and aided by cellular protein LEDGF/p75. In addition, IN is also crucial for proper virion maturation as it interacts with the viral RNA genome to ensure encapsulation of ribonucleoprotein complexes within the protective capsid core. These key functions make IN an attractive target for the development of inhibitors with various mechanisms of action. We conducted a high-throughput screen (HTS) of ∼370,000 compounds using a homogeneous time-resolved fluorescence-based assay capable of capturing diverse inhibitors targeting multifunctional IN. Our approach revealed chemical scaffolds containing diketo acid moieties similar to IN strand transfer inhibitors (INSTIs) as well as novel compounds distinct from all current IN inhibitors including INSTIs and allosteric integrase inhibitors (ALLINIs). Specifically, our HTS resulted in the discovery of compound 12, with a novel IN inhibitor scaffold amenable for chemical modification. Its more potent derivative 14e similarly inhibited catalytic activities of WT and mutant INs containing archetypical INSTI- and ALLINI-derived resistant substitutions. Further SAR-based optimization resulted in compound 22 with an antiviral EC50 of ∼58 μM and a selectivity index of >8500. Thus, our studies identified a novel small-molecule scaffold for inhibiting HIV-1 IN, which provides a promising platform for future development of potent antiviral agents to complement current HIV-1 therapies.
Collapse
Affiliation(s)
- Daniel Adu-Ampratwum
- Division
of Medicinal Chemistry & Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
| | - Yuhan Pan
- Division
of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
| | - Pratibha C. Koneru
- Division
of Infectious Diseases, School of Medicine, University of Colorado, Aurora, Colorado 80045, United States
| | - Janet Antwi
- Division
of Medicinal Chemistry & Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
| | - Ashley C. Hoyte
- Division
of Infectious Diseases, School of Medicine, University of Colorado, Aurora, Colorado 80045, United States
| | - Jacques Kessl
- Department
of Chemistry & Biochemistry, The University
of Southern Mississippi, Hattiesburg, Mississippi 39406, United States
| | - Patrick R. Griffin
- Department
of Molecular Medicine, The Scripps Research
Institute, Jupiter, Florida 33458, United
States
| | - Mamuka Kvaratskhelia
- Division
of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
- Division
of Infectious Diseases, School of Medicine, University of Colorado, Aurora, Colorado 80045, United States
| | - James R. Fuchs
- Division
of Medicinal Chemistry & Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
| | - Ross C. Larue
- Division
of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
- Department
of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, Ohio 43210, United States
| |
Collapse
|
11
|
Wu P, Zhang Y, Cheng Y. Sequential Ag(I) Salt and Chiral N-Heterocyclic Carbene Catalysis Enables Enantioselective and Diastereoselective Construction of Complex Heterocyclic Molecules and the Switch of Stereoselectivity. J Org Chem 2022; 87:2779-2796. [PMID: 35041426 DOI: 10.1021/acs.joc.1c02703] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Organic reactions under cascade catalysis provide a powerful strategy to construct molecules of complexed structures. Reported herein is the sequential silver(I) salt and chiral N-heterocyclic carbene (NHC) catalyzed enantioselective and diastereoselective synthesis of a diversity of unprecedented fused heterocyclic compounds from the reactions of readily available N'-((2-alkynyl-3-pyridinyl)methylene)hydrazides with 2-aroylvinylcinnamaldehydes. Both reaction pathways and stereoselectivity were steered conveniently and efficiently by the employment of different NHCs and bases, enabling the selective preparation of pentacyclic ring-fused 1,6-naphthyridine derivatives and 1,6-naphthyridine-substituted tricyclic products in moderated to good yields with high enantioselectivity and diastereoselectivity. Mechanisms accounting for the selective transformations, especially the effect of base and chiral NHC catalyst on the reaction course and stereochemistry of products, were also discussed.
Collapse
Affiliation(s)
- Pei Wu
- College of Chemistry, Beijing Normal University, Beijing 100875, China
| | - Yue Zhang
- College of Chemistry, Beijing Normal University, Beijing 100875, China
| | - Ying Cheng
- College of Chemistry, Beijing Normal University, Beijing 100875, China
| |
Collapse
|
12
|
Abstract
A hallmark of retroviral replication is establishment of the proviral state, wherein a DNA copy of the viral RNA genome is stably incorporated into a host cell chromosome. Integrase is the viral enzyme responsible for the catalytic steps involved in this process, and integrase strand transfer inhibitors are widely used to treat people living with HIV. Over the past decade, a series of X-ray crystallography and cryogenic electron microscopy studies have revealed the structural basis of retroviral DNA integration. A variable number of integrase molecules congregate on viral DNA ends to assemble a conserved intasome core machine that facilitates integration. The structures additionally informed on the modes of integrase inhibitor action and the means by which HIV acquires drug resistance. Recent years have witnessed the development of allosteric integrase inhibitors, a highly promising class of small molecules that antagonize viral morphogenesis. In this Review, we explore recent insights into the organization and mechanism of the retroviral integration machinery and highlight open questions as well as new directions in the field.
Collapse
|
13
|
Wang Y, Xiang S, Tan B. Application in Drugs and Materials. AXIALLY CHIRAL COMPOUNDS 2021:297-315. [DOI: 10.1002/9783527825172.ch11] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/01/2023]
|
14
|
Li K, Lv Y, Lu Z, Yun X, Yan S. An environmentally benign multi-component reaction: Highly regioselective synthesis of functionalized 2-(diarylphosphoryl)-1,2-dihydro-pyridine derivatives. GREEN SYNTHESIS AND CATALYSIS 2021. [DOI: 10.1016/j.gresc.2021.10.008] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
|
15
|
Shaikh MH, Subhedar DD, Khedkar VM, Shingate BB. [Et 3NH][HSO 4]-Catalyzed One-Pot Solvent Free Syntheses of Functionalized [1,6]-Naphthyridines and Biological Evaluation. Polycycl Aromat Compd 2021. [DOI: 10.1080/10406638.2021.1970587] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Mubarak H. Shaikh
- Department of Chemistry, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad, Maharashtra, India
- Department of Chemistry, Radhabai Kale Mahila Mahavidyalaya, Ahmednagar, Maharashtra, India
| | - Dnyaneshwar D. Subhedar
- Department of Chemistry, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad, Maharashtra, India
| | - Vijay M. Khedkar
- Department of Pharmaceutical Chemistry, School of Pharmacy, Vishwakarma University, Pune, Maharashtra, India
| | - Bapurao B. Shingate
- Department of Chemistry, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad, Maharashtra, India
| |
Collapse
|
16
|
Debyser Z, Bruggemans A, Van Belle S, Janssens J, Christ F. LEDGINs, Inhibitors of the Interaction Between HIV-1 Integrase and LEDGF/p75, Are Potent Antivirals with a Potential to Cure HIV Infection. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2021; 1322:97-114. [PMID: 34258738 DOI: 10.1007/978-981-16-0267-2_4] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
A permanent cure remains the greatest challenge in the field of HIV research. In order to reach this goal, a profound understanding of the molecular mechanisms controlling HIV integration and transcription is needed. Here we provide an overview of recent advances in the field. Lens epithelium-derived growth factor p75 (LEDGF/p75), a transcriptional coactivator, tethers and targets the HIV integrase into transcriptionally active regions of the chromatin through an interaction with the epigenetic mark H3K36me2/3. This finding prompted us to propose a "block-and-lock" strategy to retarget HIV integration into deep latency. A decade ago, we pioneered protein-protein interaction inhibitors for HIV and discovered LEDGINs. LEDGINs are small molecule inhibitors of the interaction between the integrase binding domain (IBD) of LEDGF/p75 and HIV integrase. They modify integration site selection and therefore might be molecules with a "block-and-lock" mechanism of action. Here we will describe how LEDGINs may become part in the future functional cure strategies.
Collapse
Affiliation(s)
- Zeger Debyser
- Molecular Virology and Gene Therapy, Department of Pharmacological and Pharmaceutical Sciences, KU Leuven, Leuven, Belgium.
| | - Anne Bruggemans
- Molecular Virology and Gene Therapy, Department of Pharmacological and Pharmaceutical Sciences, KU Leuven, Leuven, Belgium
| | - Siska Van Belle
- Molecular Virology and Gene Therapy, Department of Pharmacological and Pharmaceutical Sciences, KU Leuven, Leuven, Belgium
| | - Julie Janssens
- Molecular Virology and Gene Therapy, Department of Pharmacological and Pharmaceutical Sciences, KU Leuven, Leuven, Belgium
| | - Frauke Christ
- Molecular Virology and Gene Therapy, Department of Pharmacological and Pharmaceutical Sciences, KU Leuven, Leuven, Belgium
| |
Collapse
|
17
|
Lavanya M, Lin C, Mao J, Thirumalai D, Aabaka SR, Yang X, Mao J, Huang Z, Zhao J. Synthesis and Anticancer Properties of Functionalized 1,6-Naphthyridines. Top Curr Chem (Cham) 2021; 379:13. [PMID: 33624162 DOI: 10.1007/s41061-020-00314-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Accepted: 11/12/2020] [Indexed: 12/29/2022]
Abstract
The burgeoning interest in synthesis and biological applications of 1,6-naphthyridines reflects the importance of 1,6-naphthyridines in the synthetic as well as medicinal chemistry fields. Specially, 1,6-naphthyridines are pharmacologically active, with variety of applications such as anticancer, anti-human immunodeficiency virus (HIV), anti-microbial, analgesic, anti-inflammatory and anti-oxidant activities. Although collective recent synthetic developments have paved a path to a wide range of functionalized 1,6-naphthyridines, a complete correlation of synthesis with biological activity remains elusive. The current review focuses on recent synthetic developments from the last decade and a thorough study of the anticancer activity of 1,6-naphthyridines on different cancer cell lines. Anticancer activity has been correlated to 1,6-naphthyridines using the literature on the structure-activity relationship (SAR) along with molecular modeling studies. Exceptionally, at the end of this review, the utility of 1,6-naphthyridines displaying activities other than anticancer has also been included as a glimmering extension.
Collapse
Affiliation(s)
- Mallu Lavanya
- State Key Laboratory of Oil and Gas Reservoir Geology and Exploitation, Southwest Petroleum University, Chengdu, 610500, Xindu, People's Republic of China.,School of Chemistry and Chemical Engineering, Southwest Petroleum University, Chengdu, 610500, People's Republic of China
| | - Chong Lin
- State Key Laboratory of Oil and Gas Reservoir Geology and Exploitation, Southwest Petroleum University, Chengdu, 610500, Xindu, People's Republic of China.
| | - Jincheng Mao
- State Key Laboratory of Oil and Gas Reservoir Geology and Exploitation, Southwest Petroleum University, Chengdu, 610500, Xindu, People's Republic of China.
| | | | - Sreenath Reddy Aabaka
- State Key Laboratory of Oil and Gas Reservoir Geology and Exploitation, Southwest Petroleum University, Chengdu, 610500, Xindu, People's Republic of China
| | - Xiaojiang Yang
- State Key Laboratory of Oil and Gas Reservoir Geology and Exploitation, Southwest Petroleum University, Chengdu, 610500, Xindu, People's Republic of China
| | - Jinhua Mao
- State Key Laboratory of Oil and Gas Reservoir Geology and Exploitation, Southwest Petroleum University, Chengdu, 610500, Xindu, People's Republic of China
| | - Zhiyu Huang
- School of Chemistry and Chemical Engineering, Southwest Petroleum University, Chengdu, 610500, People's Republic of China
| | - Jinzhou Zhao
- State Key Laboratory of Oil and Gas Reservoir Geology and Exploitation, Southwest Petroleum University, Chengdu, 610500, Xindu, People's Republic of China
| |
Collapse
|
18
|
Targeting protein self-association in drug design. Drug Discov Today 2021; 26:1148-1163. [PMID: 33548462 DOI: 10.1016/j.drudis.2021.01.028] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2020] [Revised: 07/24/2020] [Accepted: 01/26/2021] [Indexed: 01/05/2023]
Abstract
Protein self-association is a universal phenomenon essential for stability and molecular recognition. Disrupting constitutive homomers constitutes an original and emerging strategy in drug design. Inhibition of homomeric proteins can be achieved through direct complex disruption, subunit intercalation, or by promoting inactive oligomeric states. Targeting self-interaction grants several advantages over active site inhibition because of the stimulation of protein degradation, the enhancement of selectivity, substoichiometric inhibition, and by-pass of compensatory mechanisms. This new landscape in protein inhibition is driven by the development of biophysical and biochemical tools suited for the study of homomeric proteins, such as differential scanning fluorimetry (DSF), native mass spectrometry (MS), Förster resonance energy transfer (FRET) spectroscopy, 2D nuclear magnetic resonance (NMR), and X-ray crystallography. In this review, we discuss the different aspects of this new paradigm in drug design.
Collapse
|
19
|
Grignard Reagent Utilization Enables a Practical and Scalable Construction of 3-Substituted 5-Chloro-1,6-naphthyridin-4-one Derivatives. Molecules 2020; 25:molecules25235667. [PMID: 33271818 PMCID: PMC7730554 DOI: 10.3390/molecules25235667] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2020] [Revised: 11/26/2020] [Accepted: 11/27/2020] [Indexed: 11/28/2022] Open
Abstract
A robust, practical, and scalable approach for the construction of 3-substituted 5-chloro-1,6-naphthyridin-4-one derivatives 13 via the addition of Grignard reagents to 4-amino-2-chloronicotinonitrile (15) was developed. Starting with various Grignard reagents, a wide range of 3-substituted 5-chloro-1,6-naphthyridin-4-one derivatives 13 were conveniently synthesized in moderate-to-good yields through addition–acidolysis–cyclocondensation. In addition, the robustness and applicability of this synthetic route was proven on a 100 g scale, which would enable convenient sample preparation in the preclinical development of 1,6-naphthyridin-4-one-based MET-targeting antitumor drug candidates.
Collapse
|
20
|
Patel M, Cianci C, Allard CW, Parker DD, Simmermacher J, Jenkins S, Mcauliffe B, Minassian B, Discotto L, Krystal M, Meanwell NA, Naidu BN. Design, synthesis and SAR study of novel C2-pyrazolopyrimidine amides and amide isosteres as allosteric integrase inhibitors. Bioorg Med Chem Lett 2020; 30:127516. [PMID: 32860982 DOI: 10.1016/j.bmcl.2020.127516] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2020] [Revised: 08/18/2020] [Accepted: 08/20/2020] [Indexed: 10/23/2022]
Abstract
The design, synthesis and structure-activity relationships associated with a series of C2-substituted pyrazolopyrimidines as potent allosteric inhibitors of HIV-1 integrase (ALLINIs) are described. Structural modifications to these molecules were made in order to examine the effect on potency and, for select compounds, pharmacokinetic properties. We examined a variety of C2-substituted pyrazolopyrimidines and found that the C2-amide derivatives demonstrated the most potent antiviral activity of this class against HIV-1 infection in cell culture.
Collapse
Affiliation(s)
- Manoj Patel
- Departments of Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA; ViiV Healthcare, 36 East Industrial Parkway, Branford, CT 06405, USA.
| | - Christopher Cianci
- Virology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA
| | - Christopher W Allard
- Departments of Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA
| | - Dawn D Parker
- Departments of Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA; ViiV Healthcare, 36 East Industrial Parkway, Branford, CT 06405, USA
| | - Jean Simmermacher
- Departments of Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA; ViiV Healthcare, 36 East Industrial Parkway, Branford, CT 06405, USA
| | - Susan Jenkins
- Departments of Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA; ViiV Healthcare, 36 East Industrial Parkway, Branford, CT 06405, USA
| | - Brian Mcauliffe
- Virology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA; ViiV Healthcare, 36 East Industrial Parkway, Branford, CT 06405, USA
| | - Beatrice Minassian
- Virology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA
| | - Linda Discotto
- Virology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA
| | - Mark Krystal
- Virology, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA; ViiV Healthcare, 36 East Industrial Parkway, Branford, CT 06405, USA
| | - Nicholas A Meanwell
- Departments of Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA
| | - B Narasimhulu Naidu
- Departments of Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA; ViiV Healthcare, 36 East Industrial Parkway, Branford, CT 06405, USA
| |
Collapse
|
21
|
Structure-based amelioration of PXR transactivation in a novel series of macrocyclic allosteric inhibitors of HIV-1 integrase. Bioorg Med Chem Lett 2020; 30:127531. [DOI: 10.1016/j.bmcl.2020.127531] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2020] [Revised: 08/27/2020] [Accepted: 08/28/2020] [Indexed: 02/06/2023]
|
22
|
Tsuruoka R, Yoshikawa N, Konishi T, Yamano M. Asymmetric Synthesis of a 5,6,7,8-Tetrahydro-1,6-naphthyridine Scaffold Leading to Potent Retinoid-Related Orphan Receptor γt Inverse Agonist TAK-828F. J Org Chem 2020; 85:10797-10805. [PMID: 32701287 PMCID: PMC7445745 DOI: 10.1021/acs.joc.0c01311] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
![]()
An asymmetric synthesis
of the tetrahydronaphthyridine scaffold of TAK-828F as a RORγt
inverse agonist has been developed. The synthesis features a newly
discovered atom-economical protocol for Heck-type vinylation of chloropyridine
using ethylene gas, an unprecedented formation of dihydronaphthyridine
directly from 2-vinyl-3-acylpyridine mediated by ammonia, and a ruthenium-catalyzed
enantioselective transfer hydrogenation as key steps. This represents
the first example of the enantioselective synthesis of a 5,6,7,8-tetrahydro-1,6-naphthyridine
compound. The new synthesis is also free of chromatography or distillation
purification processes and therefore qualifies for extension to large-scale
manufacture.
Collapse
Affiliation(s)
- Ryoji Tsuruoka
- Process Chemistry, Pharmaceutical Sciences, Takeda Pharmaceutical Company Limited, 17-85 Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Naoki Yoshikawa
- Process Chemistry, Pharmaceutical Sciences, Takeda Pharmaceutical Company Limited, 17-85 Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Takahiro Konishi
- Process Chemistry, Pharmaceutical Sciences, Takeda Pharmaceutical Company Limited, 17-85 Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| | - Mitsuhisa Yamano
- Process Chemistry, Pharmaceutical Sciences, Takeda Pharmaceutical Company Limited, 17-85 Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan
| |
Collapse
|
23
|
Ultrasonic promoted synthesis of 1,6-naphthyridine derivatives catalyzed by solid acid in water. Tetrahedron Lett 2020. [DOI: 10.1016/j.tetlet.2020.152144] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
24
|
Mancinelli M, Bencivenni G, Pecorari D, Mazzanti A. Stereochemistry and Recent Applications of Axially Chiral Organic Molecules. European J Org Chem 2020. [DOI: 10.1002/ejoc.201901918] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Michele Mancinelli
- Department of Industrial Chemistry “Toso Montanari” University of Bologna Viale Risorgimento 4 40136 Bologna Italy
| | - Giorgio Bencivenni
- Department of Industrial Chemistry “Toso Montanari” University of Bologna Viale Risorgimento 4 40136 Bologna Italy
| | - Daniel Pecorari
- Department of Industrial Chemistry “Toso Montanari” University of Bologna Viale Risorgimento 4 40136 Bologna Italy
| | - Andrea Mazzanti
- Department of Industrial Chemistry “Toso Montanari” University of Bologna Viale Risorgimento 4 40136 Bologna Italy
| |
Collapse
|
25
|
Li G, Meanwell NA, Krystal MR, Langley DR, Naidu BN, Sivaprakasam P, Lewis H, Kish K, Khan JA, Ng A, Trainor GL, Cianci C, Dicker IB, Walker MA, Lin Z, Protack T, Discotto L, Jenkins S, Gerritz SW, Pendri A. Discovery and Optimization of Novel Pyrazolopyrimidines as Potent and Orally Bioavailable Allosteric HIV-1 Integrase Inhibitors. J Med Chem 2020; 63:2620-2637. [PMID: 32081010 DOI: 10.1021/acs.jmedchem.9b01681] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
The standard of care for HIV-1 infection, highly active antiretroviral therapy (HAART), combines two or more drugs from at least two classes. Even with the success of HAART, new drugs with novel mechanisms are needed to combat viral resistance, improve adherence, and mitigate toxicities. Active site inhibitors of HIV-1 integrase are clinically validated for the treatment of HIV-1 infection. Here we describe allosteric inhibitors of HIV-1 integrase that bind to the LEDGF/p75 interaction site and disrupt the structure of the integrase multimer that is required for the HIV-1 maturation. A series of pyrazolopyrimidine-based inhibitors was developed with a vector in the 2-position that was optimized by structure-guided compound design. This resulted in the discovery of pyrazolopyrimidine 3, which was optimized at the 2- and 7-positions to afford 26 and 29 as potent allosteric inhibitors of HIV-1 integrase that exhibited low nanomolar antiviral potency in cell culture and encouraging PK properties.
Collapse
Affiliation(s)
- Guo Li
- Department of Early Discovery Chemistry, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut 06492, United States
| | - Nicholas A Meanwell
- Department of Chemistry, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut 06492, United States
| | - Mark R Krystal
- Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut 06492, United States
| | - David R Langley
- Department of Computer-Aided Drug Design & Molecular Analytics, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-4000, United States
| | - B Narasimhulu Naidu
- Department of Chemistry, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut 06492, United States
| | - Prasanna Sivaprakasam
- Department of Computer-Aided Drug Design & Molecular Analytics, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-4000, United States
| | - Hal Lewis
- Department of Molecular Structure and Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-4000, United States
| | - Kevin Kish
- Department of Molecular Structure and Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-4000, United States
| | - Javed A Khan
- Department of Molecular Structure and Design, Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543-4000, United States
| | - Alicia Ng
- Department of Materials Science, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut 06492, United States
| | - George L Trainor
- Department of Chemistry, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States
| | - Christopher Cianci
- Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut 06492, United States
| | - Ira B Dicker
- Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut 06492, United States
| | - Michael A Walker
- Department of Chemistry, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut 06492, United States
| | - Zeyu Lin
- Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut 06492, United States
| | - Tricia Protack
- Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut 06492, United States
| | - Linda Discotto
- Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut 06492, United States
| | - Susan Jenkins
- Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut 06492, United States
| | - Samuel W Gerritz
- Department of Early Discovery Chemistry, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut 06492, United States
| | - Annapurna Pendri
- Department of Early Discovery Chemistry, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut 06492, United States
| |
Collapse
|
26
|
Design, synthesis and biological evaluation of imidazole and oxazole fragments as HIV-1 integrase-LEDGF/p75 disruptors and inhibitors of microbial pathogens. Bioorg Med Chem 2020; 28:115210. [DOI: 10.1016/j.bmc.2019.115210] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2019] [Revised: 10/23/2019] [Accepted: 11/05/2019] [Indexed: 12/17/2022]
|
27
|
Engelman AN. Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition. J Biol Chem 2019; 294:15137-15157. [PMID: 31467082 DOI: 10.1074/jbc.rev119.006901] [Citation(s) in RCA: 47] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Antiretroviral inhibitors that are used to manage HIV infection/AIDS predominantly target three enzymes required for virus replication: reverse transcriptase, protease, and integrase. Although integrase inhibitors were the last among this group to be approved for treating people living with HIV, they have since risen to the forefront of treatment options. Integrase strand transfer inhibitors (INSTIs) are now recommended components of frontline and drug-switch antiretroviral therapy formulations. Integrase catalyzes two successive magnesium-dependent polynucleotidyl transferase reactions, 3' processing and strand transfer, and INSTIs tightly bind the divalent metal ions and viral DNA end after 3' processing, displacing from the integrase active site the DNA 3'-hydroxyl group that is required for strand transfer activity. Although second-generation INSTIs present higher barriers to the development of viral drug resistance than first-generation compounds, the mechanisms underlying these superior barrier profiles are incompletely understood. A separate class of HIV-1 integrase inhibitors, the allosteric integrase inhibitors (ALLINIs), engage integrase distal from the enzyme active site, namely at the binding site for the cellular cofactor lens epithelium-derived growth factor (LEDGF)/p75 that helps to guide integration into host genes. ALLINIs inhibit HIV-1 replication by inducing integrase hypermultimerization, which precludes integrase binding to genomic RNA and perturbs the morphogenesis of new viral particles. Although not yet approved for human use, ALLINIs provide important probes that can be used to investigate the link between HIV-1 integrase and viral particle morphogenesis. Herein, I review the mechanisms of retroviral integration as well as the promises and challenges of using integrase inhibitors for HIV/AIDS management.
Collapse
Affiliation(s)
- Alan N Engelman
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215 Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115
| |
Collapse
|
28
|
Lima LM, Alves MA, do Amaral DN. Homologation: A Versatile Molecular Modification Strategy to Drug Discovery. Curr Top Med Chem 2019; 19:1734-1750. [PMID: 31393250 DOI: 10.2174/1568026619666190808145235] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2019] [Revised: 07/04/2019] [Accepted: 07/22/2019] [Indexed: 11/22/2022]
Abstract
Homologation is a concept introduced by Gerhard in 1853 to describe a homologous series in organic chemistry. Since then, the concept has been adapted and used in medicinal chemistry as one of the most important strategies for molecular modification. The homologation types, their influence on physico-chemical properties and molecular conformation are presented and discussed. Its application in lead-identification and lead optimization steps, as well as its impact on pharmacodynamics/pharmacokinetic properties and on protein structure is highlighted from selected examples. • Homologation: definition and types • Homologous series in nature • Comparative physico-chemical and conformational properties • Application in lead-identification and lead-optimization • Impact on pharmacodynamic property • Impact on pharmacokinetic property • Impact on protein structure • Concluding remarks • Acknowledgment • References.
Collapse
Affiliation(s)
- Lídia M Lima
- Instituto Nacional de Ciencia e Tecnologia de Farmacos e Medicamentos (INCT-INOFAR;, Laboratorio de Avaliacao e Sintese de Substancias Bioativas, Universidade Federal do Rio de Janeiro, CCS, Cidade Universitaria, Rio de Janeiro- RJ, Brazil
| | - Marina A Alves
- Instituto Nacional de Ciencia e Tecnologia de Farmacos e Medicamentos (INCT-INOFAR;, Laboratorio de Avaliacao e Sintese de Substancias Bioativas, Universidade Federal do Rio de Janeiro, CCS, Cidade Universitaria, Rio de Janeiro- RJ, Brazil
| | - Daniel N do Amaral
- Instituto Nacional de Ciencia e Tecnologia de Farmacos e Medicamentos (INCT-INOFAR;, Laboratorio de Avaliacao e Sintese de Substancias Bioativas, Universidade Federal do Rio de Janeiro, CCS, Cidade Universitaria, Rio de Janeiro- RJ, Brazil
| |
Collapse
|